{"id":"W2405208786","doi":"10.1016/j.jval.2016.03.233","title":"Manager, Health Economics and Patient Access","year":2016,"lang":"en","type":"article","venue":"Value in Health","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Notre-Dame; University of Calgary; Novartis (Canada)","funders":"","keywords":"Fingolimod; Natalizumab; Teriflunomide; Discontinuation; Medicine; Glatiramer acetate; Internal medicine; Medical prescription; Multiple sclerosis; Brace; Physical therapy; Pharmacology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005693244,0.0002210079,0.0004239464,0.0008027029,0.00132844,0.00776365,0.0006037554,0.004543969,0.05053778],"category_scores_gemma":[0.05272208,0.0002313877,0.0002317755,0.0008990591,0.00106221,0.003731325,0.00115329,0.00392533,0.003179195],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00308829,"about_ca_system_score_gemma":0.008346353,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002707952,"about_ca_topic_score_gemma":0.003949134,"domain_scores_codex":[0.9944993,0.002420157,0.0002957344,0.0002571478,0.001906074,0.0006214287],"domain_scores_gemma":[0.9606884,0.01877448,0.004763518,0.0007568489,0.004022145,0.01099466],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000151049,0.0002448933,0.02594858,0.0002266137,0.00007168313,0.0007031889,0.0007177819,0.0007534703,0.0002909698,0.1313136,0.7076961,0.1318821],"study_design_scores_gemma":[0.0001618724,0.0002577011,0.02546166,0.000764743,0.00007778304,0.003192749,0.003293915,0.002893129,0.0005676373,0.1221681,0.8410514,0.0001092814],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.01700775,0.01205003,0.002424891,0.8235801,0.005597671,0.00004692151,0.0004356081,0.00007454857,0.1387825],"genre_scores_gemma":[0.6610524,0.02064072,0.003970713,0.1411946,0.0268312,0.0001362155,0.0002960883,0.0001707762,0.1457073],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.05053778,"threshold_uncertainty_score":0.1690657,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02306125399034103,"score_gpt":0.2639696351950183,"score_spread":0.2409083812046772,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}